Document is current
Any future updates will be listed below
-
Authors
Grosjean, Parker https://orcid.org/0000-0002-2024-119X
Shevade, Kaivalya https://orcid.org/0000-0001-5681-3260
Nguyen, Cuong
Ancheta, Sarah
Mader, Karl
Franco, Ivan
Heo, Seok-Jin https://orcid.org/0009-0004-4830-8319
Lewis, Greyson https://orcid.org/0000-0002-0824-2093
Zhao, Dehua
Tolani, Bhairavi
Boggess, Steven
Di Domenico, Angelique https://orcid.org/0000-0002-0592-2560
Ullian, Erik https://orcid.org/0000-0003-2077-8584
Shafer, Shawn
Litterman, Adam
Przybyla, Laralynne https://orcid.org/0000-0002-8598-4779
Keiser, Michael J. https://orcid.org/0000-0002-1240-2192
Ifkovits, Jamie
Yala, Adam
Kampmann, Martin https://orcid.org/0000-0002-3819-7019
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 6 November 2025
First Online: 17 December 2025
Competing interests
: M.K. is a coscientific founder of Montara Therapeutics and serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Alector and Montara Therapeutics, and is an advisor to Modulo Bio and Recursion Therapeutics. M.K. is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, and on a US Patent application on in vivo screening methods. J.I., C.N., I.F., D.Z. and S.S. are employees of GSK. The other authors declare no competing interests.
